Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.60 |
| ▸ | TK1 | P04183 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836268 | 0.96 | HPRT1 (0.61) | HPRT1TK1NOS1CYP1A2PNP | |
| SCHEMBL6061495 | 0.86 | HPRT1 (0.58) | HPRT1TK1NOS1CYP1A2PNP | |
| SCHEMBL489058 | 0.85 | HPRT1 (0.56) | HPRT1NOS1PNP | |
| SCHEMBL3793007 | 0.85 | HPRT1 (0.58) | HPRT1TK1NOS1CYP1A2PNP | |
| SCHEMBL9739844 | 0.84 | HPRT1 (0.60) | HPRT1NOS1PNP | |
| SCHEMBL10511442 | 0.84 | HPRT1 (0.53) | HPRT1TK1NOS1CYP1A2 | |
| SCHEMBL9663134 | 0.84 | HPRT1 (0.55) | HPRT1TK1NOS1 | |
| SCHEMBL9515983 | 0.84 | HPRT1 (0.72) | HPRT1PNP | |
| Water SCHEMBL11469150 | 0.83 | HPRT1 (0.56) | HPRT1NOS1PNPXDH | |
| SCHEMBL9662657 | 0.83 | HPRT1 (0.56) | HPRT1NOS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1594987-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | Hoser, Mark J. (GB) | 2005-11-16 | — | — | EP | claimed |
| WO-2004074503-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | HOSER MARK J (GB) | 2004-09-02 | — | — | WO | claimed |
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | claimed |
| US-5446045-A | Viricides for treating AIDS, viral diseases | TRIPLEX PHARMACEUTICAL CORPORATION | 1995-08-29 | — | — | US | claimed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250223639-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12344890-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3750544-B1 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | UNIV EMORY (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| EP-0112364-A1 | NOVEL DERIVATIVES OF GUANINE II | Astra Läkemedel Aktiebolag (SE) | 1984-07-04 | — | — | EP | disclosed |
| EP-0103552-A2 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1984-03-21 | — | — | EP | disclosed |
| EP-0103551-A2 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1984-03-21 | — | — | EP | disclosed |
| WO-1984000167-A1 | NOVEL DERIVATIVES OF GUANINE I | ASTRA LAEKEMEDEL AB (SE) | 1984-01-19 | — | — | WO | disclosed |
| WO-1984000168-A1 | NOVEL DERIVATIVES OF GUANINE II | ASTRA LAEKEMEDEL AB (SE) | 1984-01-19 | — | — | WO | disclosed |
| WO-1982002202-A1 | NOVEL DERIVATIVES OF GUANINE | ASTRA LAEKEMEDEL AB (SE) | 1982-07-08 | — | — | WO | disclosed |
| EP-0055239-A1 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223639-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | RNGTT, POLRMT, POLM | HPRT1 127/4885TK1 104/4885NOS1 3544/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | HPRT1 14/4885TK1 5/4885NOS1 182/4885 |
| US-12344890-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | RNGTT, POLRMT, POLM | HPRT1 127/4885TK1 104/4885NOS1 3544/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | HPRT1 17/4885TK1 24/4885NOS1 1294/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | HPRT1 17/4885TK1 24/4885NOS1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.